- Home
- UTL vs JANX Comparison
UTL vs JANX Comparison
Compare UTL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UTL | JANX |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 944.1M | 1.0B |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UTL | JANX |
|---|---|---|
| Price | $53.40 | $17.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 18 |
| Target Price | ★ $54.00 | $36.24 |
| AVG Volume (30 Days) | 128.5K | ★ 896.5K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 1.37 | N/A |
| EPS | ★ 2.11 | N/A |
| Revenue | ★ $536,000,000.00 | $10,000,000.00 |
| Revenue This Year | $16.49 | $194.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.13 | ★ N/A |
| Revenue Growth | ★ 8.33 | N/A |
| 52 Week Low | $46.91 | $12.12 |
| 52 Week High | $57.26 | $35.34 |
Technical Indicators
Market Signals| Indicator | UTL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 48.18 |
| Support Level | $52.10 | $15.83 |
| Resistance Level | $53.80 | $19.14 |
| Average True Range (ATR) | 0.94 | 0.86 |
| MACD | 0.35 | 0.11 |
| Stochastic Oscillator | 99.86 | 41.11 |
Price Performance
Historical ComparisonAbout UTL UNITIL Corporation
Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.